TLR 7/8 작용제 : 표적 집단, 경쟁 구도, 시장 예측(2034년)

TLR 7/8 Agonist - Target Population, Competitive Landscape, and Market Forecast - 2034

US $ 7,950 ￦ 11,145,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 16,717,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 22,290,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 33,435,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

주요 하이라이트 :

• TLR 7/8 작용제는 MyD88 의존성 신호전달을 활성화하고 IFN-α, TNF-α, IL-12와 같은 사이토카인을 유도함으로써 강력한 Th1형 면역 반응을 일으킵니다. 종양 미세환경을 재구성하고 면역체크포인트 억제제와 시너지 효과를 발휘할 수 있는 능력에서 종양, 백신, 면역질환 영역에서 유망한 약제로 자리매김하고 있어 선택성과 안전성을 높이는 혁신이 진행되고 있습니다.
• TLR 7/8 작용제는 진행성 흑색종, 비소세포 폐암(NSCLC), 근육층 비침습성 방광암(NMIBC), 경뇨도적 방광 종양 절제술(TURBT) 나중에 고부담 암을 대상으로 하는 임상시험이 진행 중이며, 현행 치료가 충분히 대응할 수 없는 영역에서 항종양 면역반응을 강화하는 전략적 역할을 담당하고 있습니다.
• 자연 면역 및 획득 면역 활성화에서 중요한 역할에도 불구하고, 현재 시장에 미국 FDA 승인된 전신 투여 TLR 7/8 작용제가 존재하지 않습니다. 유일하게 승인된 국소 제제는 ALDARA(imiquimod)이지만 이미 제네릭이 유통되고 있습니다. 이 상황은 특히 종양학 및 감염성 영역에서 표적형 및 효과적인 치료 옵션을 제공할 수 있는 신규 특허 보호 TLR 7/8 작용제에 대한 큰 미충족 요구를 부각시킵니다.
• 모든 적응증에 대해 승인된 TLR 7/8 작용제가 존재하지 않는다는 사실은 중요한 치료 갭을 나타내며, 이 신흥 경로를 표적으로 하는 후기 개발 후보 약물에 선행자 이익을 가져올 수 있습니다.
• 신흥 TLR 7/8 작용제의 파이프라인에는 Eikon Therapeutics의 EIK1001이나 SURGE Therapeutics의 resiquimod(STM-416) 등 유망한 후보약이 포함되어 있어 현재 미국 FDA에서 승인된 전신투여약이 존재하지 않는 상황에 대응하여 종양분야를 비롯한 종양 분야를 비롯한 치료 옵션을 확대하려는 움직임이 가속화되고 있음을 반영합니다.

본 보고서에서는 미국, EU4(독일, 프랑스, 이탈리아, 스페인), 영국, 일본에서 TLR 7/8 작용제 시장 배경, 경쟁 구도, 시장 동향을 상세하게 조사·분석했습니다.

또한 본 보고서는 현재 치료의 실태, 신규 치료제의 동향, 각 치료제 시장 점유율, 2021년부터 2034년까지의 7MM(주요 7개 시장 : 미국, EU4, 영국, 일본)에 있어서 시장 규모의 현황 및 예측을 제공합니다. 또한 미충족 의료 수요에 대해서도 다루어 시장의 잠재성을 평가하고 최적의 사업 기회를 파악하기 위한 내용이 되고 있습니다.

대상 지역

• 미국
• EU4(독일, 프랑스, 이탈리아, 스페인) 및 영국
• 일본

조사 기간 : 2021-2034년

조사 범위 :

• 주요 이벤트, 주요 요약, TLR 7/8 작용제에 관한 기술적 개설, 작용기전, 출시 완료 및 신규 치료제의 해설
• 경쟁 환경의 종합적 분석, 예측, 치료율의 장래의 성장 가능성, 치료제의 침투에 관한 인사이트
• 현재 및 신규의 치료제의 전체상, 후기·중기·초기 개발 단계에 있는 치료제의 상세 프로파일
• TLR 7/8 작용제의 상세한 리뷰, 시장 규모 추이와 예측, 치료제별 시장 점유율, 상세한 전제조건, 근거
• SWOT 분석, 전문가/KOL의 견해, 치료 선호 등에 의한 동향 이해 : 7MM에 있어서의 사업 전략의 책정이 우위

TLR 7/8 작용제 보고서 : 인사이트

• 표적 집단
• 치료 접근
• 파이프라인 분석
• 시장 규모 및 동향
• 기존 및 미래 시장 기회

TLR 7/8 작용제 보고서 : 주요 강점

• 10년간의 예측
• 주요 7개국 커버리지
• 주요 경쟁약
• 치료제의 보급률과 주요 시장 예측의 전제조건

TLR 7/8 작용제 보고서 : 평가

• 현재의 치료법
• 미충족 수요(Unmet Needs)
• 파이프라인 제품프로파일
• 시장의 매력
• 정성 분석(SWOT)

목차

제1장 중요한 인사이트

제2장 보고서 서문

제3장 주요 요약

제4장 주요 사건

제5장 시장 예측 수법

제6장 주요 7개국 시장 : 개요

• 시장 점유율(%) 분포(2024년) : 적응증별
• 시장 점유율(%) 분포(2034년) : 적응증별

제7장 TLR 7/8 작용제 : 배경 및 개요

• TLR 7/8 작용제의 진화
• 치료

제8장 표적 집단

• 주요 조사 결과
• 가정 및 근거
• 역학 및 시나리오
  • 주요 7개국 주요 적응증 총 증례 수
  • 주요 7개국 주요 적응증 총 적격 환자 수
  • 주요 7개국 주요 적응증 총 치료 증례 수
• 미국
• EU4 및 영국
• 일본

제9장 신흥 약제

• 주요 기업
• EIK1001 : Eikon Therapeutics
  • 제품 설명
  • 기타 개발 활동
  • 임상 개발
  • 안전성과 유효성
  • 애널리스트의 견해
• Resiquimod(STM-416) : SURGE Therapeutics

제10장 TLR 7/8 작용제 : 주요 7개국 시장 분석

• 주요 조사 결과
• 예측의 전제조건
• 시장 전망
• 속성 분석
• 주요 7개국 시장 규모
• 주요 7개국 시장 규모 : 치료제별
• 미국
• EU4 및 영국
• 일본

제11장 미충족 수요(Unmet Needs)

제12장 SWOT 분석

제13장 KOL의 견해

제14장 시장 접근성 및 보험 적용

제15장 부록

제16장 Delveinsight의 제공 능력

제17장 면책사항

제18장 DelveInsight 정보

KTH

영문 목차

영문목차

Key Highlights:

• TLR7/8 agonists activate MyD88-dependent signaling to drive strong Th1-type immune responses, inducing cytokines like IFN-a, TNF-a, and IL-12. Their ability to remodel the tumor microenvironment and synergize with checkpoint inhibitors positions them as promising agents in oncology, vaccines, and immune disorders, with ongoing innovations enhancing selectivity and safety.
• TLR7/8 agonists are progressing through clinical trials targeting high-burden cancers such as advanced melanoma, non-small cell lung cancer (NSCLC), non-muscle invasive bladder cancer (NMIBC), and post-transurethral resection of bladder tumor (TURBT) settings, highlighting their strategic role in addressing critical gaps by potentiating antitumor immune responses where current treatments fall short.
• Despite the critical role of TLR7/8 agonists in activating innate and adaptive immunity, no US FDA-approved systemic therapies currently exist in the market, and the only approved topical agent, ALDARA (imiquimod), have generics available in the market. This situation underscores a significant unmet need for novel, patented TLR7/8 agonists that can provide targeted and effective treatment options, particularly in oncology and infectious diseases.
• The absence of approved TLR 7/8 agonists across all indications underscores a significant therapeutic gap, presenting a first-mover advantage for late-stage candidates targeting this emerging pathway.
• The emerging pipeline of TLR7/8 agonists features promising candidates like Eikon Therapeutics' EIK1001, and SURGE Therapeutics' resiquimod (STM-416), among others, reflecting growing momentum to address the current lack of US FDA-approved systemic therapies and expand treatment options in oncology and beyond.

DelveInsight's "TLR 7/8 Agonist" - Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the TLR 7/8 agonist, historical and projected epidemiological data, competitive landscape as well as the TLR 7/8 agonist market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The TLR 7/8 agonist market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM TLR 7/8 agonist market size from 2020 to 2034. The report also covers current TLR 7/8 agonist treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

TLR 7/8 Agonist Understanding and Treatment Algorithm

TLR 7/8 Agonist Overview

TLR7 and TLR8, located in intracellular endosomes, play a critical role in tumor immune surveillance by triggering Th1-type innate immune responses and modulating T cell function. Their broad expression across cancers positions them as potential diagnostic, prognostic, and therapeutic targets. Recent advances in small-molecule TLR7/8 agonists have demonstrated their ability to induce cytokines and chemokines, enhancing both innate and adaptive antitumor immunity. These agonists show promise not only in cancer immunotherapy but also as vaccine adjuvants, making them attractive candidates for tumor-targeted treatments.

TLR 7/8 Agonist Clinical Relevance

TLR7/8 agonists are under clinical evaluation across high-burden oncology indications, including advanced melanoma, NSCLC, NMIBC, and TURBT, among others, reflecting their potential to enhance antitumor immunity in settings with significant unmet therapeutic needs.

TLR 7/8 Agonist Epidemiology

The TLR 7/8 agonist epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases in selected indications for TLR 7/8 agonist, total eligible patient pool in selected indications for TLR 7/8 agonist, and total treated cases in selected indications for TLR 7/8 agonist in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

NSCLC

• About 80-85% of all lung cancers are NSCLC.
• In the US, in 2024, there were ~200,000 new cases of NSCLC cancer (~115,500 in men and ~89,300 in women.
• The three main histological subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell (undifferentiated) carcinoma. In the US, ~59% of all lung cancers are adenocarcinomas. About 25% of all lung cancers are squamous cell carcinoma. Large cell (undifferentiated) carcinoma makes up ~6% of all lung cancers.
• NSCLC occurs more frequently in males, who account for roughly 56% of diagnosed cases in the US.

NMIBC

• In 2024, the US recorded the highest prevalence of non-muscle invasive bladder cancer among the 7MM, with around 600,000 cases-a number projected to rise over the forecast period.
• In 2024, the highest non muscle invasive bladder cancer prevalence among EU4 and the UK was in Italy, while the lowest number of cases was in France.
• In Japan, the highest number of NMIBC stage-specific cases was in the Ta stage, accounting for approximately 60% in 2024.

TLR 7/8 Agonist Drug Chapters

The drug chapter segment of the TLR 7/8 agonist reports includes a detailed analysis of TLR 7/8 agonist early-, mid-, and late-stage (Phase I, Phase II and Phase III) pipeline drugs. It also helps understand the TLR 7/8 agonist's clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug the latest news and press releases.

Emerging Drugs

Emerging TLR7/8 agonists include Eikon Therapeutics' EIK1001, and SURGE Therapeutics' resiquimod (STM-416), among others, reflecting growing interest in harnessing innate immunity to enhance cancer immunotherapy outcomes.

EIK1001: Eikon Therapeutics

EIK1001, a systemically administered TLR 7/8 co-agonist, has shown promising clinical activity both as a monotherapy and in combination with anti-PD-(L)1 agents in Phase I studies across multiple solid tumors, including advanced metastatic melanoma. It is currently in a Phase II/III trial as first-line therapy for advanced melanoma and in Phase II development for squamous and nonsquamous NSCLC.

In May 2025, Eikon Therapeutics announced that new data from its oncology portfolio, generated in collaboration with independent investigators, were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held from May 30 to June 3, 2025.

The presentations spotlighted first-in-human and combination therapy findings from its two lead clinical programs, including EIK1001-006 (TeLuRide-006; Abstract TPS9604), an adaptive Phase II/III trial evaluating EIK1001 in combination with pembrolizumab for advanced melanoma. Alongside ASCO, Eikon also discussed recent milestones from TeLuRide-006 and TeLuRide-005 trial.

Resiquimod (STM-416): SURGE Therapeutics

Resiquimod is an injectable biodegradable hydrogel designed for extended, localized release of cancer immunotherapies directly at the site of surgical tumor resection.

In January 2023, SURGE Therapeutics received US FDA clearance of its IND application to initiate a Phase I/IIa trial evaluating its lead intraoperative immunotherapy, SURGERx with resiquimod, for preventing recurrence or progression following Transurethral Resection of Bladder Tumor (TURBT) in patients with recurrent high-grade Non-Muscle Invasive Bladder Cancer (NMIBC). The study aims to enhance post-resection outcomes by delivering targeted immunotherapy during surgery.

TLR 7/8 Agonist Market Outlook

The TLR 7/8 agonist landscape remains largely untapped, with ALDARA (imiquimod) as the only FDA-approved agent, available in generic topical form. This leaves a significant white space for innovation in systemic oncology applications. Emerging candidates such as Eikon Therapeutics' EIK1001 and SURGE Therapeutics' resiquimod (STM-416), among others, are advancing through different stages of trials, demonstrating potential both as monotherapy and in synergistic combinations with checkpoint inhibitors. As interest in next-generation immuno-oncology combinations accelerates, these agents could play a pivotal role in expanding treatment paradigms, provided they can establish clear efficacy and manageable safety profiles.

TLR 7/8 Agonist Uptake

This section focuses on the uptake rate of potential approved and emerging TLR 7/8 agonist expected to be launched in the market during 2020-2034.

TLR 7/8 Agonist Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II and Phase I. It also analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunity for TLR 7/8 agonist market growth over the forecasted period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for TLR 7/8 agonist emerging therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on TLR 7/8 agonist's evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM.

Their opinion helps understand and validate current and emerging therapy treatment patterns or TLR 7/8 agonists market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of TLR 7/8 agonist, explaining its mechanism, and therapies (current and emerging).
• Comprehensive insight into the Competitive Landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the TLR 7/8 agonist market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis expert insights/KOL views, and treatment preferences that help shape and drive the 7MM TLR 7/8 agonist market.

TLR 7/8 Agonist Report Insights

• TLR 7/8 Agonist Targeted Patient Pool
• TLR 7/8 Agonist Therapeutic Approaches
• TLR 7/8 Agonist Pipeline Analysis
• TLR 7/8 Agonist Market Size and Trends
• Existing and Future Market Opportunity

TLR 7/8 Agonist Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

TLR 7/8 Agonist Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)

Key Questions:

• What would be the TLR 7/8 agonist total market size, the market size by therapies, market share (%) distribution in 2034? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2034?
• Which is the most lucrative market for TLR 7/8 agonist?
• Which drug accounts for maximum sales among TLR 7/8 agonists?
• What are the pricing variations among different geographies for approved therapies?
• How has the reimbursement landscape for TLR 7/8 agonists evolved since the first one was approved? Do patients face any access issues driven by reimbursement decisions?
• What are the risks, burdens, and unmet needs of treatment with TLR 7/8 agonist? What will be the growth opportunities across the 7MM for the patient population on TLR 7/8 agonist?
• What are the key factors hampering the growth of the TLR 7/8 agonist market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for TLR 7/8 agonist?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the TLR 7/8 agonist market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the UK, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the attribute analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Market Forecast Methodology

6. Market Overview at a Glance in the 7MM

• 6.1. Market Share (%) Distribution by Indication in 2024
• 6.2. Market Share (%) Distribution by Indication in 2034

7. TLR 7/8 Agonist: Background and Overview

• 7.1. Introduction
• 7.2. Evolution of TLR 7/8 Agonist
• 7.3. Treatment

8. Target Patient Pool

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: 7MM
• 8.3. Epidemiology Scenario in the 7MM
  • 8.3.1. Total Cases in Selected Indications for TLR 7/8 Agonist in the 7MM
  • 8.3.2. Total Eligible Patient Pool in Selected Indications for TLR 7/8 Agonist in the 7MM
  • 8.3.3. Total Treated Cases in Selected Indications for TLR 7/8 Agonist in the 7MM
• 8.4. The US
  • 8.4.1. Total Cases in Selected Indications for TLR 7/8 Agonist in the US
  • 8.4.2. Total Eligible Patient Pool in Selected Indications for TLR 7/8 Agonist in the US
  • 8.4.3. Total Treated Cases in Selected Indications for TLR 7/8 Agonist in the US
• 8.5. EU4 and the UK
  • 8.5.1. Total Cases in Selected Indications for TLR 7/8 Agonist in EU4 and the UK
  • 8.5.2. Total Eligible Patient Pool in Selected Indications for TLR 7/8 Agonist in EU4 and the UK
  • 8.5.3. Total Treated Cases in Selected Indications for TLR 7/8 Agonist in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Cases in Selected Indications for TLR 7/8 Agonist in Japan
  • 8.6.2. Total Eligible Patient Pool in Selected Indications for TLR 7/8 Agonist in Japan
  • 8.6.3. Total Treated Cases in Selected Indications for TLR 7/8 Agonist in Japan

9. Emerging Therapies

• 9.1. Key Cross Competition
• 9.2. EIK1001: Eikon Therapeutics
  • 9.2.1. Drug Description
  • 9.2.2. Others Developmental Activities
  • 9.2.3. Clinical Trials Information
  • 9.2.4. Safety and Efficacy
  • 9.2.5. Analyst's View
• 9.3. Resiquimod (STM-416): SURGE Therapeutics
  • 9.3.1. Drug Description
  • 9.3.2. Others Developmental Activities
  • 9.3.3. Clinical Trials Information
  • 9.3.4. Safety and Efficacy
  • 9.3.5. Analyst's View

List of drugs to be continued in the final report...

10. TLR 7/8 Agonist: the 7MM Analysis

• 10.1. Key Findings
• 10.2. Key Market Forecast Assumptions
  • 10.2.1. Cost Assumptions and Rebates
  • 10.2.2. Pricing Trends
  • 10.2.3. Analogue Assessment
  • 10.2.4. Launch Year and Therapy Uptakes
• 10.3. Market Outlook
• 10.4. Attribute Analysis
• 10.5. Total Market Size of TLR 7/8 Agonist in the 7MM
• 10.6. Market Size of TLR 7/8 Agonist by Therapies in the 7MM
• 10.7. The US Market Size
  • 10.7.1. Total Market Size of TLR 7/8 Agonist in the US
  • 10.7.2. Market Size of TLR 7/8 Agonist by Therapies in the US
• 10.8. EU4 and the UK Market Size
  • 10.8.1. Total Market Size of TLR 7/8 Agonist in EU4 and the UK
  • 10.8.2. Market Size of TLR 7/8 Agonist by Therapies in EU4 and the UK
• 10.9. Japan Market Size
  • 10.9.1. Total Market Size of TLR 7/8 Agonist in Japan
  • 10.9.2. Market Size of TLR 7/8 Agonist by Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. The US
  • 14.1.1. Centre for Medicare and Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. The UK
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Acronyms and Abbreviations
• 15.2. Bibliography
• 15.3. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight